Long Beach, CANCT07357597Now EnrollingIRB Ready

Stomatitis Clinical Trial in Long Beach, CA

Access cutting-edge stomatitis treatment through this clinical trial at a research site in Long Beach. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Long Beach location

Preparing your pre-screening questions…

Expert Care in Long Beach

Access stomatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stomatitis treatment provided free

Apply for This Long Beach Location

Check if you qualify for this stomatitis clinical trial in Long Beach, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Long Beach

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Long Beach site if eligible
  4. 4Begin participation

About This Stomatitis Study in Long Beach

This is a multicenter, open-label, single-arm study of prophylaxis for Dato-DXd-related stomatitis in eligible patients with metastatic or inoperable locally recurrent breast cancer or locally advanced or metastatic Epidermal Growth Factor Receptor-Mutated (EGFRm) non-small cell lung cancer.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Patients are eligible to be included in the study only if all the following criteria apply: Disease Characteristics
Patients with any of the following disease characteristics are eligible (specific population subject to FDA Dato-DXd label): • Patients with unresectable or metastatic HR+/HER2- (IHC 0, IHC 1+, or IHC 2+/ISH-) breast cancer who have received prior ET and chemotherapy for unresectable or metastatic disease. OR • Adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy. Participants will be enrolled upon FDA approval on use of Dato-DXd for this indication. OR • Patients with locally advanced or metastatic EGFRm NSCLC who have received prior EGFR-directed therapy and platinum-based chemotherapy. Age
Patient must be ≥ 18 years, at the time of signing the informed consent. Type of Patient and Disease Characteristics-
Has documentation that Dato-DXd will be prescribed for the labelled indication and has not received any dose of Dato-DXd prior to enrollment.
Is willing to comply with use of prophylactic dexamethasone mouthwash at the start of first infusion and throughout Dato-DXd administration.
ECOG performance status 0 or 1.
Has adequate bone marrow function (hemoglobin ≥ 9 g/dL; red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment).
All women of childbearing potential must have a negative serum pregnancy test result at screening. Informed Consent
Capable of giving signed informed consent as described in the protocol which includes compliance with the requirements and restrictions listed in the ICF and the protocol.

Exclusion Criteria

Patients are excluded from the study if any of the following criteria apply:
Has received Dato-DXd prior to enrollment. Medical Conditions
As judged by the investigator, any evidence of cardiac, pulmonary, vascular, and other renal conditions which in the investigator's opinion makes it undesirable for the patient to participate in the study.
Has any-grade active and uncontrolled stomatitis or mouth ulcers at baseline (participants with prior medical history of stomatitis or mouth ulcers are eligible).
Use of steroid-containing mouthwash is contraindicated in, including but not limited to:
Active oral infections (eg, viral, bacterial, or fungal), where the use of a steroid-containing mouthwash may impair local immune response and delay healing
Known hypersensitivity or allergy to corticosteroids or any excipients contained in the mouthwash formulation
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections (participants with localized fungal infections of skin or nails are eligible).
Has clinically significant corneal disease.
Has a history of severe hypersensitivity reactions to either the drug or inactive ingredients of Dato-DXd (including, but not limited to, polysorbate 80).
Has a history of severe hypersensitivity reactions to other monoclonal antibodies.
Is pregnant, or breastfeeding, or planning to become pregnant. Other Exclusions
Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.
Previous enrollment in the present study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Long Beach?

Yes, this clinical trial (NCT07357597) has an active research site in Long Beach, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stomatitis Treatment Options in Long Beach, CA

If you're searching for stomatitis treatment options in Long Beach, CA, this clinical trial (NCT07357597) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Long Beach research site is actively enrolling participants for this clinical trial. You'll receive care from experienced stomatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Long Beach?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Long Beach, CA